Neuroinflammation is recognized as early event or key accelerant in the pathobiology of persistent CNS infections, HIV b r a i n r e s e a r c h 1 5 3 7 ( 2 0 1 3 ) 2 7 3 -2 8 2
Introduction
Neuroinflammation is recognized as early event or key accelerant in the pathobiology of persistent CNS infections, HIV understanding of the physiologic role of the endogenous cannabinoid (endocannabinoid) system, has advanced the exploration of cannabinoid receptor compounds for novel CNS therapies (Piomelli, 2003, Mechoulam and Parker, 2013) . The CB 1 receptor is abundant in the brain (Howlett et al., 2002) , signals progenitor cells, neurogenesis and development (Aguado et al., 2007 , Diaz-Alonso et al., 2012 , can be neuroprotective, and mediates many of the psychoactive effects of cannabinoids (Mackie, 2005 . The CB 2 receptor is present mainly on immune cells of both the periphery and CNS (Howlett et al., 2002) . Its activation is immunomodulatory, regulatory and neuroprotective (Atwood and Mackie, 2010) , through reduction of microglia/macrophage activation, migration (Romero-Sandoval et al., 2009 , Fraga et al., 2011 , and decrease in proinflammatory cytokines and toxins Griffin-Thomas, 2009, Bouchard et al., 2012) . That CB 2 expression increases in disease states associated with neural inflammation (Benito et al., 2008, Pacher and Mechoulam, 2011) adds to its appeal as a therapeutic target.
Borna Disease Virus (BDV) is a veterinary pathogen causing encephalitic illnesses in a variety of mammalian and bird hosts (Lipkin and Briese, 2007) . In experimental species it provides an informative model for study of persistent CNS infections. Experimental Borna Disease, based on well-characterized rodent models of viral-induced neuroinflammation and degeneration and dependant on host strain, genetics and age of exposure, is used for study of acute and chronic CNS infections and their treatments. Male Lewis rats infected at adolescence develop persistent infection, inflammation and regional neurodegeneration (Narayan et al., 1983 , Solbrig et al., 1994 , Planz et al., 1995 . One week treatment of adolescentinfected Lewis rats (BD rats) by the general cannabinoid agonist WIN55,212-2 (with CB 1 and CB 2 receptor activity) limits reactive gliogenesis and macrophage activity in favor of new cell, particularly oligodendroglia, development. The neuroprotective effect depends on restricting microglial activation and is independent of endocannabinoid (anandamide, 2-AG) levels and antiviral effect (Solbrig et al., 2010) .
Here, we test the efficacy of the general cannabinoid agonist WIN 55,212-2 and compare it with the more specific CB 2 agonist HU-308 as adjunctive long-term therapy in chronic viral encephalitis. Since CB 2 receptors are upregulated in response to lesion or inflammation in a variety of cell types (Cabral and Griffin-Thomas, 2009) , are known to be renewed during microglia proliferation and action (Maresz et al., 2005 , Racz et al., 2008 , and inhibit populations of microglia/macrophages after neural injuries (Zarruk et al., 2012) , we test the specific hypothesis that administration of a selective CB 2 agonist provides sustained neuroprotective and anti-inflammatory effects.
Results
BrdU (Fig. 1A) . Double label IHC with cell-type specific markers were used to evaluate phenotype of new cells. ED1 antibody, which recognizes an antigen in lysosomal membranes of phagocytes, is expressed by activated microglia and the majority of tissue macrophages (Bauer et al., 1994 3A) and HU was superior to WIN in reducing inflammatory histopathology (Fig. 3B ).
To determine cellular localization of CB 2 receptors in BD rat brain, double label IHC studies using antibodies to CB 2 receptors, and markers for activated microglia/macrophages (ED1), T cells (CD3) and astroglia (GFAP) and neurons (NeuN) were performed. CB2 receptor immunoreactivity in patterns that were mainly membrane or submembrane, was present on inflammatory and glial cells of untreated BD rats (Fig. 4) . Cells were identified as activated microglia, astrocytes, or T cells based on cell marker immunostaining, morphology and location, confirming receptor presence with inflammation and immune activation during BD viral encephalitis. Delicate staining outside the double-labeled cell was interpreted as punctate staining of cross sections of cellular processs. Overall the highest immunoreactivity (IR) was cell-associated at meningeal edges and perivascular locations. Blood vessels of BD rats showed intense signal at outer surface walls while sparse CB 2 staining was associated with blood vessels in uninfected brains (not pictured).
CB 2 receptors were targets of HU, with patterns of CB 2 receptor-like IR altered by treatment (Fig. 5) . Diffuse (basal) CB 2 receptor staining in untreated BD brains and irregular granular patterns of CB 2 receptor-like immunoreactivity (IR) in WIN-treated brains were seen. In contrast, CB 2 receptorlike immunoreactivity (IR) appeared as coarse inclusions or clusters compressed within the cell, a pattern consistent with internalization of receptors during agonist exposure. Fewer meningeal CB 2 R-IR cells were found in this group.
To test a direct viral effect of WIN or HU, levels of bornaviral N (nucleoprotein) segment RNA were measured by qRT-PCR of BD, BDþWIN, BDþHU rats (n¼ 7 per group) Significant numeric reductions in copies vRNA/μg tissue in hippocampus of animals treated with WIN were found, along with vRNA reductions in hippocampus of HU treated subjects. In PFC and striatum, where within group variability was high, WIN and HU had no statistically significant effects on vRNA. There was no clear association between virus and either proor anti-inflammatory effects across the 3 groups. Overall, a useful anti-inflammatory effect without detrimental increase in virus had been achieved by HU treatment.
Discussion
Testing the effects of synthetic cannabinoids as adjunctive therapy in chronic viral encephalitis, we found the specific CB 2 receptor agonist HU-308 superior to the general cannabinoid agonist WIN55,212-2 in providing longer term antiinflammatory effects and preservation of newborn cells.
The anti-inflammatory action was through mechanisms involving glial cells, in particular CB 2 receptor agonist suppression of microglia activation. Modest antiviral effects were produced by both HU-308 and WIN55,212-2. Whereas one week treatment with WIN had protected against inflammatory-mediated new cell loss in a previous study (Solbrig et al., 2010) , the effect was not found when treatment was extended for 2 weeks. Histologic similarities in inflammation and lack of new cell protection between WINtreated and drug-naive BD rats after 2 weeks treatment were interpreted as BD rats showing tolerance to WIN's antiinflammatory effect, limiting the efficacy of the general cannabinoid agonist WIN to sometime between 1 and 2 weeks of treatment. In other words, WIN had produced decreasing effect with repeated dosing. Mechanisms of tolerance to WIN could include saturation or downregulation of CB 1 receptors, uncoupling CB 1 stimulation from progenitor cell or neuron biologic processes of protection, or uncoupling CB 1 stimulation from control elements in immunologic effects in the CNS and periphery.
To achieve long term anti-inflammatory efficacy and new cell protection, a strategy of selective CB 2 receptor stimulation was chosen, based on known coordinated responses of the endocannabinoid system to injury. Specifically, local endocannabinoid levels increase with tissue injury or inflammation at the same time as CB 2 receptors on inflammatory and some parenchymal cells are induced by immune cell transcription factors or soluble inflammatory factors. IFNγ and granulocyte macrophage-colony stimulating factor (GM-CSF) promote CB 2 expression in microglia (Maresz et al., 2005 , Racz et al., 2008 while stimulation of CB 2 receptors reduces microglia migration (Romero-Sandoval et al., 2009) production of TNF-α (Sagredo et al., 2009 , Zarruk et al., 2012 , reactive oxygen species (Han et al., 2009) , and regulates expression of iNOS and CCR2 (Racz et al., 2008) . This constant supply of CB 2 receptors, renewed during microglia proliferation and action, represented a druggable potentially nontolerizing target for long term inflammation reduction.
In our experiments, the anti-inflammatory action achieved with HU-308 was through mechanisms involving glial cells, mainly activated microglia, in which CB 2 receptors were upregulated in response to neural injury. Finding CB 2 receptor-like IR on microglia was altered by HU treatment in patterns consistent with receptor internalization, while lack of receptor internalization by WIN maintained microglia and active morphology, raise the possibility of functional selectivity or biased agonism between these 2 synthetic cannabinoid ligands. Internalization of CB 2 receptors to different extents with different agonists, differential activation of specific downstream signaling pathways, and the inability of WIN stimulation to internalize CB 2 receptors, are all effects that have been shown in vitro (Atwood et al., 2012) .
The differential effects of WIN and HU also may relate to the mixed or more promiscuous pharmacologic effects of WIN. Although WIN and HU have similar in vitro binding affinity to CB 2 (Pertwee, 2010) , WIN is an aminoalkylindole with significant agonist activity at CB 1 , CB 2 , and the vanilloid receptor VR1; HU-308 is a bicyclic compound and a selective CB 2 agonist (Pertwee, 2010) ; and TRPV1 (transient receptor potential vanilloid 1 receptor) activation is proinflammatory. b r a i n r e s e a r c h 1 5 3 7 ( 2 0 1 3 ) 2 7 3 -2 8 2
Neuronal TRPV1 cation channels are best known as mediators of inflammatory pain in dorsal spinal cord, with a role in neuron-mediated glial activation in primary sensory ganglia of rodents (Chen et al., 2009 , Cavanaugh et al., 2011 . In rat TRPV1 is also expressed in astrocytes and microglia (Doly et al., 2004 , Kim et al., 2006 . That TRPV1 cation channel activity has been shown in vitro to upregulate microglial reactive oxygen species production by induction and/or maintenance of NADPH oxidase activity Eder, 2010, 2011) , connects WIN to inflammation. The interaction of cannabinoids and viral infection has been studied in vitro, in animal models, and in individuals with infections with recreational or medicinal use of cannabinoids. Cannabinoids worsen disease when inflammatory and cell-directed antiviral responses required for viral clearance are reduced, with HSV-2, Kaposi's sarcoma herpesvirus KSHV, Vesicular stomatitis virus VSV, HCV, Coxpox, HIV, and SIV as examples (reviewed in Reiss, 2010) . On the other hand, cannabinoids benefit disease when host inflammatory response is associated with pathology, not recovery, e.g. Theiler's murine virus TMV (reviewed in Reiss, 2010) , BDV Hermanowicz, 2008, Solbrig et al., 2010) , also HIV and SIV (Molina et al., 2010 , reviewed in Rom and Persidsky, 2013 Important contributions to understanding cannabinoid/ viral interactions are from the expanding experimental evidence of direct effects of cannabinoids on retroviral replication. Viral replication in immune tissues is reduced in CB 2 agonist treated microglia (Rock et al., 2007) or in THC treated animals with SIV where suppression of viral replication is a consequence of suppressed inflammation (Molina et al., 2011) . Molecular mechanisms underlying the protective effects of cannabinoids and involving HIV's replication machinery are decreased HIV-1 LTR activation by CB 2 ligands in HIV-infected macrophages (Ramirez et al., 2013) . Structural mechanisms of viral reduction are alterations of cytoskeletal architecture of resting CD4þ T cells by CB 2 R agonism, where reducing F-actin levels inhibit actin reorganization and impair productive infection (Costantino et al., 2012) .
Important contributions to understanding cannabinoid/ viral disease interactions and disease modulation are emerging from experimental literature on SIV disease. Chronic Δ-9-THC IM treatment of SIVmac251 infected rhesus monkeys decreased serum and CSF viral load and tissue inflammation, reduced morbidity and mortality (Molina et al., 2010) . As a result, further investigations are focusing on stress/ immune system integration and contributions of genomewide transcriptional modulation and epigenetic factors to the cannabinoid-associated disease phenotype. Differential regulation of several genes in the NFkB system, a signaling system linked to virulence factors such as enhanced viral replication, host cell survival, immune response and invasion, has been described (Molina et al., 2011) .
As in other viral systems, interpretation of cannabinoid treatment effects on BDV is complicated because of the variety of interactions between virus and inflammation. For example, reduced viral load might decrease inflammation or alternatively, reduced viral load could be a consequence of a more robust inflammatory response. Of structures studied, the striatum, with its brain parenchyma still largely intact at this stage of infection, has the potential to most clearly render cannabinoid effects in the BD rat. The striatum is infected later than PFC and hippocampus (Solbrig et al., 1994 (Solbrig et al., , 1998 , has less neovascularization and tissue remodeling (Solbrig et al., 2010) , and similar viral quantification across groups in this study. We see "same virus, more pathology", for example, increased ED1 staining per microscopic field in striatum of WIN and BD rats compared to HU-treated rats. Thus, in striatum, a structure normalized for virus, degree of inflammatory neuropathology is a reflection of anti-inflammatory efficacy of a drug treatment, not virus. In PFC, where neuropathology appears more advanced and vRNA numbers more divergent, there was no clear association between virus and either pro-or antiinflammatory effects across the 3 groups. And finally, in hippocampus, HU produced a modest reduction in vRNA, with the mechanism of effect on virus not known. The multiple factors involved in Borna Disease expression and progression under cannabinoid treatment cannot be completely reconciled using a single in vivo system, and a systematic approach integrated across several experimental domains will be required.
Our current results introduce the possibility that CB 2 R agonist-induced changes at cellular, tissue, or systems level could have a role in reducing productive infections by BDV, may be generalizable to other neurotropic viruses, and provide a mechanism of neuroprotection beyond reduction of inflammation. Our results also improve upon past trials managing BDV encephalitis in rats with aggressive immunosuppressive therapy that resulted in dissemination and unusual distribution of virus beyond the CNS (Stitz et al., 1991) .
Conclusion
In summary, upregulation of CB 2 expression under different pathophysiological conditions has been reported in several experimental paradigms and disease states with inflammatory or degenerative processes, diseases that have in common glial activation, inflammation, oxidative/nitrative stress, and degeneration. Targeting of CB 2 receptors with selective agonists is a new therapeutic avenue in inflammatory degenerative disorders for reduction of neuroinflammation. Our experiments show HU-308 activation of CB 2 receptors, receptors known to be renewed during microglia proliferation and action, is a nontolerizing mechanism of controlling CNS inflammation during viral encephalitis and uses a nonpsychotropic cannabinoid agonist. Contrast with WIN will help inform decisions in use of newly developed cannabinoid agonists as accessory therapy.
Experimental procedures

Animals
Male Lewis rats (Charles River Labs, Wilmington, MA, USA) were group housed on a 12 h light-dark cycle with ad libitum access to food and water. All experimental procedures were performed in compliance with the institutional (University of Manitoba) and Policy for the Humane Care and Use of Laboratory Animals guidelines. Under isofluorane anesthesia, 4-week old males were infected with Borna Disease virus (BD rats) by intracerebral injection of 1.6 Â 10 4 tissue culture infectious dose units, strain He/80, or sham-infected with sterile phosphate buffered saline (NL rats).
Drugs
Experimental rats received three 50 mg/kg ip injections of the S phase marker 5-bromo-2′-deoxyuridine (BrdU) (Sigma St Louis MO USA) at 6 h intervals at 5 weeks of age (postnatal day 34) (Solbrig et al., 2010) . BrdU incorporation was followed by 2 weeks of treatment with the non-selective cannabinoid receptor agonist R(þ)-WIN 55,212-2 (WIN) (Sigma, St Louis, MO USA) (1 mg/kg ip twice a day) or vehicle (saline) control (from postnatal day 35 to postnatal day 48) (Experiment 1) or followed by 2 weeks of treatment with the selective cannabinoid receptor 2 (CB 2 ) agonist HU-308 (Tocris/R&D Systems, Minneapolis, MN, USA) (5 mg/kg ip once a day) or vehicle (Tween-80: DMSO:saline 1:1:18 ) control (Experiment 2). The HU-308 dose was selected based on demonstration of striatal neuroprotection in a rodent model of Huntington's Disease (Sagredo et al., 2008) .
BrdU quantification, imaging and analysis
Animals were sacrificed, brains removed and processed as described (Solbrig et al., 2010) BrdU immunohistochemistry was performed to quantify 14 day old BrdU þ cells, a measure of precursor cell survival in PFC and striatum. These areas were chosen for morphologic studies because of their role on behavioral deficits of experimental BD (Solbrig et al., 1994 (Solbrig et al., , 1996 . Forty-micrometer sections were collected on a freezing microtome with the left and right hemispheres of every sixth section slide-mounted. For BrdU þ cell quantification, the following PFC subregions: orbitofrontal cortex, anterior cingulate, prelimbic cortex and infralimbic cortex, were included from Bregma þ4.20 to Bregma þ2.70 mm (Paxinos and Watson, 1998) . Striatal and subventricular regions were included from Bregma þ2.50 mm to Bregma À0.80 mm. Sections were processed for BrdU immunostaining with primary (1:400, Chemicon, Billerica, MA, USA) and biotinylated secondary antibodies (1:200 Vector Burlingame, CA, USA), developed with 3,3′-diaminobenzidine, and quantified as described (Solbrig et al., 2010 )(n¼ 4-5 per group). Double label IHC with cell-type specific markers were used to evaluate phenotype of new cells (Table 1) . (Primary antibodies were omitted in controls for staining). A one-in-six series of sections were processed for BrdU immunostaining (1:100, Accurate, Westbury, NY, USA), cell type markers, or CB 2 receptors 2 weeks after the BrdU injection.
Antigens were visualized with Alexa-488 or Alexa-546 secondary antibodies (1:1000, Molecular Probes Carlsbad, CA, USA). Colocalization of antibodies was assessed with an Olympus FluoView Laser Scanning Confocal Microscope at 600 Â using multitrack scanning and an optical section thickness of 0.50 μm in the Z-plane as described (Solbrig et al., 2010 ) (n¼ 4 per group). Data were expressed as percentage of double labeled cells for BrdU and each cell marker examined.
Virus measurements
A separate group of BD animals (n¼ 7 per experimental group) were infected at 4 weeks of age and treated from postnatal day 35 to postnatal day 48 with WIN, HU or vehicle, as above. Levels of bornaviral N (nucleoprotein) segment RNA were b r a i n r e s e a r c h 1 5 3 7 ( 2 0 1 3 ) 2 7 3 -2 8 2 measured by qRT-PCR of BD, BDþWIN, BDþHU rats in each of 3 regions: PFC, striatum, and hippocampus (Experiment 3). Previous study has shown RT-PCR quantification correlates with measurements of viral burden by focus forming unit assays (Solbrig et al., 2002) . The hippocampus was added because it is a structure reliably infected early in disease in this model. Brain regions were dissected as described (Solbrig et al., 1994 (Solbrig et al., , 2002 (Solbrig et al., , 2006 and total RNA was extracted using RNEasy Plus Universal Extraction System (Qiagen, Toronto, ON) according to manufacturer's instructions. Frozen tissues were weighed, homogenized in 150 μl Qiazol Lysis Agent with sterile disposable RNase/DNase-free pestles, brought to volume with Qiazol Lysis Agent, further disrupted by trituration. Viral RNA was eluted from silica columns with 40μl RNase free water containing 0.5 U/μl RNase Out (Invitrogen/ Life Technologies, Burlington, ON), and placed in 5 μl aliquots. Quantitative RT-PCR was conducted with a LightCycler 480 (Roche, Laval, QC) using the QuantiFast Pathogen RT-PCRþIC system (Qiagen) with primer set p40bobe-286R(GCA CCC CTC CGT GAA CAA)/p40bobe-187F(CAG TCA CGG CGC GAT ATG T), per manufacturer's instructions. Reverse transcription was conducted at 50 1C, followed by 45 cycles annealing/elongation at 60 1C and melting at 95 1C. Probe p40bobe-247T (6Fam-ATC CCA GGA CTG CAC GCT GCG TT-BBQ) (TIBMolbiol, Adelphia, NJ) was used to detect amplified product (Solbrig et al., 2002) . Serial log dilutions (10 À2 -10
À8
) of a known positive stock extract were included in each assay for quantification of vRNA. Absolute quantification with 2nd derivative maximum was established using the LightCycler 480 programming, and copies vRNA/μg tissue were determined.
Data analysis
Numeric data are represented as meanþSEM and are considered significant if po0.05. Statistical analysis was performed using Student's t tests (for comparisons of two groups) or one-way ANOVA followed by Tukey's post hoc test (for more than 2 groups). To compare co-expression of various markers in BrdU þ cells, the percentage or proportional data for differences in treatment groups, set in 2 Â 2 tables, were analyzed by Chi square test with Yate's correction. All analyses were carried out with the GraphPad Software (San Diego, CA, USA).
